

Sample Physician Billing Global Nonhospital Outpatient Setting **CMS-1500**

HEALTH INSURANCE CLAIM FORM
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

1. MEDICARE MEDICAID TRICARE CHAMPVA GROUP HEALTH PLAN FECA BLK LUNG OTHER

2. PATIENT'S NAME (Last Name, First Name, Middle Initial)

3. PATIENT'S BIRTH DATE (MM DD YY) SEX (M F)

4. INSURED'S NAME (Last Name, First Name, Middle Initial)

5. PATIENT'S ADDRESS (No., Street) CITY STATE

6. PATIENT RELATIONSHIP TO INSURED (Self Spouse Child Other)

7. INSURED'S ADDRESS (No., Street) CITY STATE

8. RESERVED FOR NUCC USE

1a. INSURED'S I.D. NUMBER (For Program in Item 1)

18. HOSPITALIZATION (FROM MM DD TO MM DD)

19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)
EXAMPLE: Axumin Fluciclovine F-18 Invoice Amount \$100.00

20. OUTSIDE LAB? (YES NO)

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (Relate A-E to service line below (24E))

22. RESUBMISSION CODE

23. PRIOR AUTHORIZATION NUMBER

	A. DATE(S) OF SERVICE			B. PLACE OF SERVICE	C. EMG	D. PROCEDURES, SERVICES, OR SUPPLIES (CPT/HCPCS) (Explain Unusual Circumstances) MODIFIER	E. DIAGNOSIS POINTER	F. \$ CHARGES	G. DAYS OR UNITS	H. POSIT Family Plan	I. ID. QUAL	J. RENDERING PROVIDER ID. #
	From MM DD YY	To MM DD YY	MM DD YY									
1	02	14	21	02	14	21	78815	A	XXXX XX	1		NPI
2	02	14	21	02	14	21	A9588	A	XXX XX	10		NPI
3												

Form Locator 19 and 24D (Global Billing Example)

- FL 19** Provide a description of the radiopharmaceutical (if required). Report the acquisition cost in Block 19 or 24D of the 1500 claim form and in the 2400 loop NTE segment of an EDI claim or as required by individual payer instructions
- FL 24D** Enter CPT[®] or HCPCS code for procedures performed and interpreted by the physician. Axumin has a product-specific HCPCS code effective January 1, 2017:
A9588 Fluciclovine F 18, diagnostic, 1 mCi

Form Locator 24G

Enter the number of units based on the CPT or HCPCS code description or per local MAC/private payer reporting instructions

Form Locator 21 and 24E

- FL 21** Enter ICD-10 code for principal diagnosis in FL 21. Possible codes include the following:
R97.21 Rising PSA following prior treatment for malignant neoplasm of the prostate
Z85.46 Personal history of malignant neoplasm of prostate
C61 Malignant neoplasm of prostate
Special note: Do not use the decimal point on the claim form, as it may cause rejection of the claim.
- FL 24E** Enter the letter corresponding to the diagnosis code for the procedure in FL 24E

Blue Earth Diagnostics, Inc. cannot guarantee coverage or reimbursement for Axumin. The existence of billing codes does not guarantee coverage and payment. Payer policies may change without notice. It is the provider's responsibility to determine and submit accurate information on claims. This includes submitting paper codes, modifiers, charges, and invoices for the services that were rendered. It is the provider's responsibility to ensure that all information on a claim is accurate. It is the provider's responsibility to check with the payer to determine whether the information contained on the claim is accurate. It is the responsibility of the provider to document the medical necessity of Axumin in the medical record.

Abbreviations: CPT, current procedural terminology; HCPCS, Healthcare Common Procedure Coding System.

CPT[®] is a registered trademark of the American Medical Association. CPT Copyright 2021 American Medical Association. All rights reserved.

Please see Axumin Important Safety Information on back.

Sample Physician Billing Global Nonhospital Outpatient Setting **CMS-1500**

AXUMIN[®]
Fluciclovine F 18 Injection

INDICATION

Axumin[®] (fluciclovine F 18) injection is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following prior treatment.

IMPORTANT SAFETY INFORMATION

- Image interpretation errors can occur with Axumin PET imaging. A negative image does not rule out recurrent prostate cancer and a positive image does not confirm its presence. The performance of Axumin seems to be affected by PSA levels. Axumin uptake may occur with other cancers and benign prostatic hypertrophy in primary prostate cancer. Clinical correlation, which may include histopathological evaluation, is recommended.
- Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available.
- Axumin use contributes to a patient's overall long-term cumulative radiation exposure, which is associated with an increased risk of cancer. Safe handling practices should be used to minimize radiation exposure to the patient and health care providers.
- Adverse reactions were reported in $\leq 1\%$ of subjects during clinical studies with Axumin. The most common adverse reactions were injection site pain, injection site erythema and dysgeusia.

To report suspected adverse reactions to Axumin, call 1-855-AXUMIN1 (1-855-298-6461) or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Axumin Prescribing Information, also available at www.axumin.com.